Can new scans predict chemo success in Triple-Negative breast cancer?

NCT ID NCT02744053

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether two advanced imaging techniques—DCE-MRI and molecular breast imaging (MBI)—can accurately assess how triple-negative breast cancer tumors respond to chemotherapy. About 96 patients will undergo these scans before, during, and after treatment. The goal is to see if these imaging methods can predict which patients are responding well, potentially helping doctors tailor treatment earlier.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Technetium Tc-99m Sestamibi (imaging tracer)
What this could lead to
If successful, this could help doctors predict which triple-negative breast cancer patients are responding to chemotherapy, potentially guiding more personalized treatment.
What could go wrong
This is a very early (phase 1) imaging study with only 96 participants, so results may not apply broadly. It focuses on measuring response, not on improving outcomes directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESTROGEN RECEPTOR NEGATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • MD Anderson League City

    Nassau Bay, Texas, 77058, United States

  • MD Anderson in Katy

    Houston, Texas, 77094, United States

  • MD Anderson in Sugar Land

    Sugar Land, Texas, 77478, United States

  • MD Anderson in The Woodlands

    The Woodlands, Texas, 77384, United States

  • Memorial Hermann Memorial City Medical Center

    Houston, Texas, 77024, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.